ProCE Banner Activity

Adding Trastuzumab Deruxtecan to the Treatment Armamentarium for Advanced Gastric Cancers

Clinical Thought
The approval of trastuzumab deruxtecan provides another treatment option for patients with HER2-positive advanced gastric cancers. Review this expert commentary on how to incorporate this agent into your practice.

Released: February 15, 2021

Expiration: February 14, 2022

No longer available for credit.

Share

Faculty

Yelena Y. Janjigian

Yelena Y. Janjigian, MD

Associate Attending Physician
Chief, 
Gastrointestinal Oncology Service
Memorial Sloan Kettering Cancer Center
Associate Professor of Medicine
Weill Cornell Medical College
New York, New York

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Daiichi Sankyo, Inc.

Faculty Disclosure

Primary Author

Yelena Y. Janjigian, MD

Associate Attending Physician
Chief, 
Gastrointestinal Oncology Service
Memorial Sloan Kettering Cancer Center
Associate Professor of Medicine
Weill Cornell Medical College
New York, New York

Yelena Y. Janjigian, MD, has disclosed that she received funds for research support from Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Genentech/Roche, Lilly, and Merck; has received consulting fees from AstraZeneca, Bayer, Bristol-Myers Squibb, Daiichi-Sankyo, Imugene, Jounce, Lilly, Merck Serono, ONO, Pfizer, Seattle Genetics, and Zymeworks Inc.; and has an ownership interest in Rgenix.